abstract
- This is a Phase 3, randomized, double-blind, placebo-controlled, efficacy and safety study of subjects with IPF treated with inhaled treprostinil over a 52-week period.
TETON RIN-PF-301
Grant
Overview
date/time interval
- January 2023 - January 2026
awarded by
Affiliation
contributor
- Veeranna Maddipati Investigator